Literature DB >> 25747934

Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway.

Albino Carrizzo1, Paola Lenzi1, Claudio Procaccini1, Antonio Damato1, Francesca Biagioni1, Mariateresa Ambrosio1, Giuseppina Amodio1, Paolo Remondelli1, Carmine Del Giudice1, Raffaele Izzo1, Alberto Malovini1, Luigi Formisano1, Vincenzo Gigantino1, Michele Madonna1, Annibale A Puca1, Bruno Trimarco1, Giuseppe Matarese1, Francesco Fornai1, Carmine Vecchione2.   

Abstract

BACKGROUND: Pentraxin 3 (PTX3), the prototype of long pentraxins, has been described to be associated with endothelial dysfunction in different cardiovascular disorders. No study has yet evaluated the possible direct effect of PTX3 on vascular function. METHODS AND
RESULTS: Through in vitro experiments of vascular reactivity and ultrastructural analyses, we demonstrate that PTX3 induces dysfunction and morphological changes in the endothelial layer through a P-selectin/matrix metalloproteinase-1 pathway. The latter hampered the detachment of endothelial nitric oxide synthase from caveolin-1, leading to an impairment of nitric oxide signaling. In vivo studies showed that administering PTX3 to wild-type mice induced endothelial dysfunction and increased blood pressure, an effect absent in P-selectin-deficient mice. In isolated human umbilical vein endothelial cells, PTX3 significantly blunted nitric oxide production through the matrix metalloproteinase-1 pathway. Finally, using ELISA, we found that hypertensive patients (n=31) have higher plasma levels of PTX3 and its mediators P-selectin and matrix metalloproteinase-1 than normotensive subjects (n=21).
CONCLUSIONS: Our data show for the first time a direct role of PTX3 on vascular function and blood pressure homeostasis, identifying the molecular mechanisms involved. The findings in humans suggest that PTX3, P-selectin, and matrix metalloproteinase-1 may be novel biomarkers that predict the onset of vascular dysfunction in hypertensive patients.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  biological markers; endothelium; hypertension; nitric oxide

Mesh:

Substances:

Year:  2015        PMID: 25747934     DOI: 10.1161/CIRCULATIONAHA.114.014822

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

Review 1.  Mechanisms of I/R-Induced Endothelium-Dependent Vasodilator Dysfunction.

Authors:  Ronald J Korthuis
Journal:  Adv Pharmacol       Date:  2017-12-08

2.  Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs.

Authors:  Yago Leira; Pablo Ameijeira; Clara Domínguez; Esteban López-Arias; Paulo Ávila-Gómez; María Pérez-Mato; Tomás Sobrino; Francisco Campos; Francesco D'Aiuto; Rogelio Leira; Juan Blanco
Journal:  Clin Oral Investig       Date:  2019-05-20       Impact factor: 3.573

Review 3.  Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules.

Authors:  Martin Wolley; Meg Jardine; Colin A Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-05       Impact factor: 8.237

4.  Serum pentraxin-3 levels and flow-mediated dilation in dipper and non-dipper hypertension.

Authors:  Çağlar Alp; Mehmet Tolga Dogru; Muhammed Karadeniz; Taner Sarak; Vahit Demir; Yunus Çelik; Hüseyin Kandemir; Üçler Kısa
Journal:  J Clin Lab Anal       Date:  2018-11-09       Impact factor: 2.352

5.  Association of genetic variants of pentraxin 3 rs3816527 with hypertension in Chronic kidney disease patients.

Authors:  Eman A E Badr; Ghada E Hamoda; Safaa I Tayel; Elsayed I Elshayeb
Journal:  Mol Cell Biochem       Date:  2016-11-12       Impact factor: 3.396

6.  Impact of acute high-intensity interval exercise on plasma pentraxin 3 and endothelial function in obese individuals-a pilot study.

Authors:  Aaron L Slusher; Brandon G Fico; Katelyn M Dodge; Ryan S Garten; Peter J Ferrandi; Alexandra A Rodriguez; Gabriel Pena; Chun-Jung Huang
Journal:  Eur J Appl Physiol       Date:  2021-02-27       Impact factor: 3.078

7.  The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.

Authors:  V Buda; M Andor; C Cristescu; M Voicu; F Cochera; P Tuduce; L Petrescu; M C Tomescu
Journal:  Ir J Med Sci       Date:  2017-02-21       Impact factor: 1.568

8.  PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer.

Authors:  Cecilia Garlanda; Barbara Bottazzi; Elena Magrini; Antonio Inforzato; Alberto Mantovani
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

9.  The responses of the inflammatory marker, pentraxin 3, to dietary sodium and potassium interventions.

Authors:  Jia-Wen Hu; Yang Wang; Chao Chu; KeKe Wang; Yu Yan; Wenling Zheng; Qiong Ma; Jian-Jun Mu
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-27       Impact factor: 3.738

10.  Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial.

Authors:  Pietro Caironi; Serge Masson; Tommaso Mauri; Barbara Bottazzi; Roberto Leone; Michela Magnoli; Simona Barlera; Filippo Mamprin; Andrea Fedele; Alberto Mantovani; Gianni Tognoni; Antonio Pesenti; Luciano Gattinoni; Roberto Latini
Journal:  Eur J Clin Invest       Date:  2016-12-14       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.